APN News

  • Tuesday, October, 2021| Today's Market | Current Time: 02:31:34
  • UpToDate Provides Free Access to Its Medical Content to All Users in Japan

    United States : UpToDate, a part of Wolters Kluwer Health, has announced that it is providing free access to its online medical content to all users in Japan. This decision was made by the company immediately following the recent earthquake and tsunami that devastated the country’s northeast coast. In addition, individuals and organizations worldwide now […]

    Boehringer Ingelheim’s lead hepatitis C compound moves into Phase III – the first within the BI HCV portfolio

    Germany: Boehringer Ingelheim has announced the study outline for the pivotal Phase III clinical trials designed to evaluate BI 201335, its investigational once-daily oral protease inhibitor, in both treatment-naïve and -experienced patients with chronic genotype-1 hepatitis C virus (HCV), the most challenging genotype to treat. In parallel, the U.S. Food and Drug Administration (FDA) has […]

    NeuroLogica Corporation Announces FDA 510(k) Clearance for BodyTomT: A Portable, Full Body, Multi-Slice CT Scanner

    United States: NeuroLogica Corporation announced the receipt of 510(k) clearance from the U.S. Food and Drug Administration (FDA) for the world’s first portable, full body, multi-slice CT scanner, the BodyTom™. (www.NeuroLogica.com) The BodyTom™ is the newest offering in NeuroLogica’s portable computed tomography imaging line. BodyTom™ is a completely portable, full body, 32 slice CT that […]

    CIGNA Enters Global Individual Health Market; Launches CIGNA Global Health Options

    United States : CIGNA ,the global leader in serving expatriates and other globally mobile individuals, has launched an international health care plan for qualified individuals who seek access to high-quality health care facilities across international boundaries. The individual consumer market is a new area of focus for CIGNA’s expatriate benefits operation. With CIGNA Global Health […]

    Erbitux Indication Extension Submitted for 1st-Line Advanced or Metastatic NSCLC in the EU

    Germany: Merck Serono, a division of Merck KGaA, Darmstadt, Germany, announced today that it has submitted an indication extension to the European Medicines Agency (EMA) for the approval of Erbitux® (cetuximab) in combination with standard 1st line platinum-based chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with high epidermal growth factor […]

    IN-TIME Enrollment Completed: BIOTRONIK Home Monitoring® Clinical Study to Assess Improvement in Heart Failure Management

    Germany: BIOTRONIK SE & Co. KG, a leading manufacturer of cardiac devices, has announced that the last chronic heart failure (HF) patient was enrolled in IN-TIME at the Schwabing Clinic in Munich, Germany, with principle investigator Professor Stefan Sack, MD. IN-TIME is a prospective, multicenter, international clinical trial that randomized 720 patients to assess the […]

    Quintiles Named a Preferred Provider to Global Health Product Development Partnership Consortium

    United States: Quintiles announced that it has been named a preferred provider to a consortium of 14 global health Product Development Partnerships (PDPs) leveraging the combined size of their pipelines to ensure the most cost effective use of their research and development dollars. PDPs are not-for-profit entities formed for the purpose of advancing global health […]

    New clinical trial data support the use of Levemir® in children aged two to five years

    New clinical trial data just published in Pediatric Diabetes show that Levemir® (insulin detemir), Novo Nordisk’s basal insulin analogue, is an equally efficacious treatment option for two to five year-old children with type 1 diabetes, compared with human basal insulin, but is associated with lower hypoglycaemic risk1. No basal insulin analogue is currently recommended for […]

    Emergent BioSolutions Observes World TB Day

    United States: Emergent BioSolutions Inc. has released the following statement in observance of World TB Day. The World TB Day 2011 campaign, “On the move against TB: Transforming the fight towards elimination,” challenges us to undertake the fight against TB with the end goal of eliminating this highly infectious and lethal disease. Two billion people […]

    Dabigatran etexilate is cost-effective for stroke prevention in atrial fibrillation, particularly in real-world clinical practice

    Germany: A new economic analysis, published online in Thrombosis and Haemostasis, suggested that Boehringer Ingelheim’s novel oral direct thrombin inhibitor dabigatran etexilate is cost-effective compared to current treatment options, particularly in real-world clinical practice.1,2 This cost-effectiveness was driven by superior prevention of ischemic stroke alongside a reduction in devastating intracranial bleeding by dabigatran etexilate compared […]